Furazolidone

Summary

Furazolidone (CHEMBL1103) is an approved small molecule (ATC G01AX06).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G01AX06
• Clinical trials: 24
• Chemistry: 225.16 Da · C8H7N3O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1103
Name	Furazolidone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5323714
ATC	G01AX06
Molecular formula	C8H7N3O5
Molecular weight	225.16
InChIKey	PLHJDBGFXBMTGZ-WEVVVXLNSA-N

SMILES: C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]

IUPAC name: 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one

Also known as: Furazolidona, Furazolidone, Furoxone, Furall, NSC-6469, SID26749310, SID29215179, SID50085998, SID8139923, FURAZOLIDONE, furazolidone, SID144205055

Patent coverage: 5,846 distinct patent families (14,492 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Ferritin light chain, Polyunsaturated fatty acid lipoxygenase ALOX15, Aldehyde dehydrogenase 1A1, Serine-protein kinase ATM, Cellular tumor antigen p53.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P51450	6.3	Potency	501.2	nM	CHEMBL_ACT_4963618
SMN1	5.25	Potency	5623	nM	CHEMBL_ACT_3867721
TP53	5	Potency	10000	nM	CHEMBL_ACT_4854131
TP53	5	Potency	10000	nM	CHEMBL_ACT_4882435

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 24.

Phase distribution

Phase	Trials
PHASE4	16
Not specified	6
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06168214	PHASE4	RECRUITING	Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication
NCT07139366	PHASE4	RECRUITING	Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
NCT01668927	PHASE4	COMPLETED	Empirical Rescue Therapies of Helicobacter Pylori Infection
NCT02894268	PHASE4	UNKNOWN	Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy
NCT02988089	PHASE4	UNKNOWN	Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment
NCT03139253	PHASE4	UNKNOWN	Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
NCT03342456	PHASE4	COMPLETED	The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers
NCT03609892	PHASE4	COMPLETED	Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
NCT03716622	PHASE4	COMPLETED	A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
NCT04264663	PHASE4	UNKNOWN	Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin
NCT04678492	PHASE4	COMPLETED	Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT04907747	PHASE4	UNKNOWN	Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication
NCT05135182	PHASE4	UNKNOWN	Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin
NCT05345210	PHASE4	UNKNOWN	Vonoprazan Hp Dual or Triple Eradication Regimes
NCT05718609	PHASE4	UNKNOWN	Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection
NCT06168084	PHASE4	COMPLETED	Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT06823791	PHASE1/PHASE2	COMPLETED	Furazolidone Quadruple Regimen Eradicate H. Pylori Infection
NCT06777732	EARLY_PHASE1	NOT_YET_RECRUITING	The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication
NCT00520949	Not specified	COMPLETED	Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection
NCT04991584	Not specified	UNKNOWN	Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection
NCT05097846	Not specified	UNKNOWN	Differences in the Eradication of Helicobacter Pylori by Different Therapies
NCT05126121	Not specified	UNKNOWN	Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection
NCT05173493	Not specified	COMPLETED	The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
NCT05176821	Not specified	UNKNOWN	Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).